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Phosphoantigen-sensitive Vg9Vd2 T cells are impor-
tant responders to infections and malignancy. How-
ever, the mechanisms by which phosphoantigens
stimulate Vg9Vd2 T cells are unclear. Here, we
synthesized phosphoantigen prodrugs and used
them to demonstrate that intracellular delivery of
phosphoantigens is required for their activity. The
pivaloyloxymethyl prodrug is the most potent phos-
phoantigen described to date, with stronger stimula-
tion of Vg9Vd2 T cells from human peripheral blood
and greater ability to induce lysis of Daudi lym-
phoma cells relative to the previously most potent
compound, (E)-4-hydroxy-3-methyl-but-2-enyl pyro-
phosphate (HMBPP). We demonstrate high binding
affinity between phosphoantigens and the intracel-
lular region of butyrophilin 3A1 (BTN3A1), localized
to the PRY/SPRY (B30.2) domain, but also affecting
themembrane proximal region. Our findings promote
a phosphoantigen prodrug approach for cancer
immunotherapy and unravel fundamental aspects
of the mechanisms of Vg9Vd2 T cell activation.
INTRODUCTION
The cells of the immune system recognize diverse foreign- and
self-antigens, generating responses that remove a variety of
foreign invaders with great specificity. As such, generation of
drug-like molecules that can regulate immune cell function
is of wide interest. The gd T cells, usually only comprising 1%–
10% of circulating T cells, have received attention recently
due to their function in cancer immunosurveillance (Bonneville
et al., 2010). Unlike the ab T cells that respond to peptides, a sub-
set of gd T cells (Vg9Vd2 T cells) detects small phosphorous-
containing compounds (phosphoantigens) (Wiemer andWiemer,
2014). The Vg9Vd2 T cells most likely gained sensitivity to phos-
phoantigens to fight bacterial infections, given that the most
potent natural phosphoantigen, (E)-4-hydroxy-3-methyl-but-2-
enyl diphosphate (HMBPP) is produced by bacteria, but not hu-
mans (Morita et al., 2007). However, phosphoantigen-activatedChemistry & Biology 21, 94cells also can suppress viruses and malignancies (Gao et al.,
2003; Wang et al., 2006).
Phosphoantigens such as HMBPP are detected by the
Vg9Vd2 T cell receptor after binding to butyrophilin 3A1
(BTN3A1) (Harly et al., 2012; Wang et al., 2013) through major
histocompatibility complex-independent mechanisms that are
not yet completely clear. Both intracellular and extracellular
binding of BTN3A1 to phosphoantigens have been recently re-
ported (Sandstrom et al., 2014; Vavassori et al., 2013). Once acti-
vated, Vg9Vd2 T cells eliminate phosphoantigen-loaded target
cells through killer cell lectin-like receptor subfamily K, member
1 receptor signaling and perforin release (Wrobel et al., 2007) and
recruit other immune cells via chemokine production (Li et al.,
2005, 2013). Therefore, development of compounds that
can bind to BTN3A1 in cancer cells to promote their lysis by
Vg9Vd2 T cells may be a promising anticancer strategy. How-
ever, questions remain about how to best target phosphoanti-
gens to their cellular binding site.
Prodrug approaches increasingly are applied to compounds
employed in antiviral and antitumor therapy (Hecker and Erion,
2008). The majority of prodrug applications of phosph(on)ates
seek to facilitate passive diffusion through the cell membrane
by masking negative charge until the compound is within the
cell, eliminating the need for endocytic uptake. Because small,
highly charged molecules can exhibit low membrane perme-
ability (Kornberg et al., 1972), synthesis of protected compounds
such as pivaloyloxymethyl (POM) derivatives (e.g., Adefovir dipi-
voxil) (Cundy, 1999; De Clercq, 2004; Marcellin et al., 2003) has
been used to advance such molecules to clinical use. We hy-
pothesized that an analogous strategy could be utilized to deter-
mine the role of cellular entry in phosphoantigen-induced T cell
activation. Upon diffusion into the cell, the protecting groups
from a phosphoantigen prodrug are thought to be released
by cellular esterases, leaving an anionic phosphoantigen inside
the cells. If intracellular/cytoplasmic binding to BTN3A1 is
required for phosphoantigen activity, onemight expect this strat-
egy to increase potency relative to the free phosphoantigen
anion, because the negatively charged phosphoantigen should
not transverse the cell membrane as readily.
With this in mind, we developed a synthetic route to make
POM-protected phosphoantigens and examined the activity
of these compounds in Vg9Vd2 T cell activation. Here, we
demonstrate that a POM-protected phosphoantigen is a highly
potent Vg9Vd2 T cell stimulus, which effectively delivers the5–954, August 14, 2014 ª2014 Elsevier Ltd All rights reserved 945
Figure 1. Chemical Structures of Phos-
phoantigens
Compounds evaluated in this study include
the control phosphoantigens (HMBPP, IPP, and
risedronate) and the phosphonate (1a), and its
protected counterparts (1b, 1c, and 1d).
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compound, while nontoxic on its own, induces potent killing of
malignant cells by Vg9Vd2 T cells, which could ultimately lead
to a new class of cancer immunotherapy agents.
RESULTS
Synthesis of a Phosphoantigen and Its
Pivaloyloxymethyl-Protected Prodrug
Vg9Vd2 T cells can be activated by direct phosphoantigens such
as HMBPP, which can occur at low nanomolar concentrations,
and indirect phosphoantigens such as the nitrogenous bis-
phosphonates, for which activation occurs at micromolar con-
centrations and is dependent upon their ability to increase the
concentration of the direct phosphoantigen isopentenyl diphos-
phate (IPP) (Sicard et al., 2005) (Figure 1). However, diphos-
phates such as HMBPP have poor pharmacokinetic properties,
most notably rapid clearance from the plasma due to phospha-
tase-mediated degradation and lowmembrane permeability due
to the negative charges of the acidic oxygen atoms at physiolog-
ical pH (Sicard et al., 2005). Therefore, we chose to generate a
series of prodrug compounds based on the more stable phos-
phonate substructure (i.e., compound 1a).
We have previously developed synthetic routes to make
POM-protected bisphosphonates, which dramatically enhance
cellular activity (Wiemer et al., 2008). To initiate the current syn-
thetic pathway, we prepared the key phosphonate salt (com-
pound 1a) and the corresponding POM-modified compounds
1b and 1c (Figure 2). Phosphonate 1a was chosen as our initial
target because it has good chemical stability (decreasing the
possibility of phosphatase metabolism) and is a modest phos-
phoantigen (Boe¨dec et al., 2008). However, to secure an efficient
preparation of the parent structure as both the disodium salt 1a
and as the POM-protected compounds 1b and 1c, we devel-
oped the synthetic sequence shown in Figure 2. Thus after prep-
aration of prenyl bromide 3 from alcohol 2, this allylic halide was
allowed to react with the anion of dimethyl methylphosphonate
to afford the phosphonate 4. Compound 4 was oxidized upon
treatment with selenium dioxide, and then the E alcohol 1d
was isolated after treatment with NaBH4 to reduce any aldehyde,
using procedures we had applied earlier to preparation of ger-
anyl (Kim et al., 2004) and then prenyl (Maalouf et al., 2007) de-
rivatives. Hydrolysis of compound 1d under standard conditions
(McKenna et al., 1977) gave the expected sodium salt 1a in good946 Chemistry & Biology 21, 945–954, August 14, 2014 ª2014 Elsevier Ltd All rights reservedyield. Unfortunately, use of compound 1d
to prepare compound 1b proved prob-
lematic. Because reaction at the hydroxyl
group proved to be competitive, a slightly
modified sequence was employed to
reach compound 1b. Phosphonate 4 firstwas converted to the bis-POM analog 6. While some of the
mono-POM mono-methyl ester 7 also was formed, this was
not a significant complication because the two compounds
were readily separable by column chromatography. Reaction
of compound 6 with selenium dioxide gave the POM-protected
target 1b in modest yield. Compound 7 then was treated inde-
pendently with selenium dioxide to obtain the closely related
compound 1c. Reduction with borohydride was avoided to mini-
mize potential decomposition of the POM groups.
Pivaloyloxymethyl-Protected Phosphoantigens Potently
Stimulate Human Peripheral Blood Vg9Vd2 T Cells
We evaluated compounds 1a and 1b for their ability to stimulate
Vg9Vd2 T cell proliferation (Figure 3A). Peripheral blood
mononuclear cells (PBMCs) derived from healthy donors were
incubated with 1 mM of compound 1a or 1b for 3 days in the
presence of interleukin 2 (IL-2). Cells were examined for the pro-
portion of cluster of differentiation 3 (CD3)+ Vg9Vd2 T cells in
live cultures 2 weeks post stimulation by flow cytometry. As
expected, treatment with HMBPP (58.5% ± 1.8%) significantly
expanded the population of Vg9Vd2 T cells as compared to
cells treated with IL-2 alone (14.6% ± 3.7%). Compound 1a
was active at the reported concentrations (Table 1) (Boe¨dec
et al., 2008). Interestingly, the POM prodrug (compound 1b)
was much more potent (57.7% ± 9.3%, at 1 mM) than com-
pound 1a and the activity approached the potency of HMBPP
(Figure 3A). This is a key finding because it demonstrates a dra-
matic increase in activity through use of a phosphoantigen
prodrug and supports an important role for intracellular delivery
of phosphoantigens.
To examine further the activity of these compounds in stimu-
lating human Vg9Vd2 T cells, compounds 1a (unprotected), 1b
(two POM groups), 1c (one POM group; one methyl group),
and 1d (two methyl groups) along with the known phosphoanti-
gens HMBPP, IPP, and risedronate (Figure 3B and Figure S1
available online) were tested in a dose response manner. As
expected, HMBPP potently expanded Vg9Vd2 T cells when
stimulated for 3 days. At all of the tested concentrations
(0.001–10 mM), HMBPP significantly increased Vg9Vd2 T cell
population (Figure 3B), where HMBPP at 0.01 mM reached the
peak of Vg9Vd2 T cell expansion to 63.3% ± 7.0%, which was
more than a 4-fold increase compared to IL-2 alone treatment
(14.6% ± 3.8%). The half maximal effective concentration
(EC50) of HMBPP in our hands was 0.00051 mM (Table 1).
Figure 2. Synthesis of a Bis-Pivaloyloxymethyl Phosphoantigen Prodrug with Potent Expansion of Vg9Vd2 T Cells from Human Peripheral
Blood
Synthetic pathways to compounds 1a–1d.
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Vg9Vd2 T cell response (Sireci et al., 2001). As expected,
1,000 mM IPP significantly expanded the Vg9Vd2 T cell popula-
tion (Figure S2). The EC50 of IPP was 36 mM, approximately
71,000-fold less potent than HMBPP (Table 1). The nitrogen-
containing bisphosphonate risedronate indirectly activates
Vg9Vd2 T cell through inhibition of farnesyl diphosphate syn-
thase and intracellular IPP accumulation (Thompson and
Rogers, 2004). Consistently, risedronate increased the Vg9Vd2
T cell population in total PBMC cultures compared to treatment
with IL-2 alone. Risedronate reached maximal stimulation at
10 mM (Figure S2). Risedronate at 1,000 mM, however, resulted
in a significant reduction of the activity, most likely due to
toxicity, similar to the effects observed with other nitrogen-
containing bisphosphonates at concentrations above 100 mM
(Miyagawa et al., 2001). To assess this toxicity, we measured
cell viability at the day 14 time point and calculated half maximal
inhibitory concentration (IC50) values for each compound
(Table 1). The selectivity indexes of HMBPP and risedronate
were 980 and 38, respectively.
Consistent with a previous study (Boe¨dec et al., 2008), the so-
dium salt 1a at 10 mM significantly increased the proportion of
Vg9Vd2 T cells in the presence of IL-2, with an EC50 of 4 mM (Fig-
ure 3B; Table 1). Because dimethyl phosphonates are metabol-
ically stable (Serafinowska et al., 1995), the dimethyl ester was
predicted to be inactive and indeed compound 1d did not
show any stimulatory effect (Figure 3B; Table 1). Replacing one
of the methyl groups with a labile POM group decreased the
EC50 value to 0.5 mM (Table 1), and this compound (1c) at
1 mM was able to expand Vg9Vd2 T cell population to 51.1 ±
6.7% compared to 18.4 ± 5.4% from treatment with the dimethyl
ester 1d at 1 mM. Compound 1b, which contains two POM
groups, was much more potent than compounds 1a, 1c, and
1d, providing an EC50 value of 0.0054 mM. Compound 1b at
0.01 mM significantly expanded the Vg9Vd2 T cell population
compared to IL-2 alone treatment and at 0.1 mM reached the
peak of stimulation up to 62.9 ± 1.6% of Vg9Vd2 T cells in
PBMC cultures, which was similar to the peak of Vg9Vd2 T cell
expansion with 0.01 mM of the potent stimulator, HMBPPChemistry & Biology 21, 94(63.3 ± 7.0%; EC50 = 0.00051 mM) (Figure 3B; Table 1). The
EC50 of compound 1b for T cell expansion was 740x lower
than that of compound 1a, illustrating the vast improvement in
efficacy seen by intracellular phosphoantigen delivery.
Pivaloyloxymethyl-Containing Compound 1b Is a Direct-
Acting Phosphoantigen
Risedronate is known to stimulate Vg9Vd2 T cell proliferation by
inhibition of farnesyl diphosphate (FPP) synthase in the mevalo-
nate pathway, which results in accumulation of IPP. To determine
whether the stimulatory effect of compound 1b on Vg9Vd2 T cell
proliferation could be caused by inhibition of FPP synthase and/
or other enzymes of the mevalonate pathway, expansion of
Vg9Vd2 T cells by risedronate and compound 1b was compared
in thepresenceorabsenceof lovastatin,which inhibits 3-hydroxy-
3-methylglutaryl-coenzyme A reductase upstream of FPP syn-
thase and prevents the synthesis of IPP. Treatment with 10 mM
lovastatin alone did not alter the proliferation of Vg9Vd2 T cells.
In the presence of 10 mM lovastatin, the stimulatory effect of ri-
sedronate at 10mMonVg9Vd2Tcell proliferationwassignificantly
reduced from 48.9 ± 20.9% to 10.6 ± 4.0%. However, the stimu-
latory effect of compound 1b on Vg9Vd2 T cell proliferation was
not significantly affected in the presence of lovastatin (Figure 3C).
The data demonstrate that prodrug 1b does not achieve its
stimulatory effect by altering the mevalonate pathway, but rather
functions by releasing a direct phosphoantigen.
Only Compound 1b Significantly Induces Vg9Vd2 T Cell
Proliferation after 2-hr Stimulation
Next, we assessed whether duration of the stimulation plays a
role in the Vg9Vd2 T cell proliferation between different com-
pounds. We hypothesized that enhanced uptake of compound
1b would require a shorter stimulation time for maximal effects.
Cells were treated with 0.1 mM HMBPP, 0.1 mM compound 1b,
100 mM compound 1a, or 100 mM risedronate for either 2 hr or
the standard 3 days, followed by IL-2 supplementation every
3 days until day 14. Flow cytometry analysis showed that all
compounds significantly expanded the Vg9Vd2 T cell population
when the cells were stimulated for 3 days. In contrast, only5–954, August 14, 2014 ª2014 Elsevier Ltd All rights reserved 947
Figure 3. Bis-POM Prodrug 1b Functions as a Direct Phosphoantigen with Elevated Potency Relative to Free Acid 1a and HMBPP
(A) POMmodification of a phosphoantigen increases cellular potency for activation of Vg9Vd2 T cells. Compounds 1a and 1bwere used to stimulate proliferation
for 3 days, and then removed. Cells were allowed to proliferate for 11 more days followed by staining for CD3 and the Vg9Vd2 TCR.
(B) Dose response curves for expansion of human peripheral blood Vg9Vd2 T cells by HMBPP and compounds 1a–1d following a 3-day stimulation.
(C) Expansion of Vg9Vd2 T cells by compound 1b is not blocked by cotreatment with lovastatin. Cells were stimulated as above with indicated concentrations of
compound 1b or risedronate in the presence or absence of 10 mM lovastatin.
(D) Cells were treated for either 2 hr or 3 days with HMBPP, risedronate, compound 1a, or 1b and expansion of Vg9Vd2 T cells was examined by flow cytometry.
All data in (B)–(D) are represented as mean ± SD, n = 3, *p < 0.05 by ANOVA with Tukey’s post-hoc analysis. See also Figure S1.
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proliferation following a 2 hr-pulse treatment (Figure 3D). These
observations indicate that compound 1b is more effective in acti-
vating the Vg9Vd2 T cell population compared to all of the other
compounds tested, including HMBPP.
The Butyrophilin 3A1 SPRY Associated Domain/sp1A/
Ryanodine Receptor Domain, B30.2 Domain, Directly
Binds Phosphoantigens
It recently was reported that BTN3A1 is required for phosphoan-
tigen detection by Vg9Vd2 T cells (Harly et al., 2012; Vavassori
et al., 2013; Wang et al., 2013). However, the exact region of
BTN3A1 where phosphoantigens bind is a matter of debate (Va-
vassori et al., 2013; Wang et al., 2013). Based on the 740x in-
crease in activity of the bis-POM prodrug, we hypothesized
that intracellular binding occurs, which is in contrast to themodel
of extracellular binding to the immunoglobulin-like V (IgV) (Va-
vassori et al., 2013). To determine whether the BTN3A1-antigen
complex forms intracellularly or extracellularly, we expressed the
recombinant extracellular IgV domain, the intracellular sp1A/rya-
nodine receptor domain/ SPRY associated domain (PRY/SPRY)
(B30.2) domain, and the butyrophilin 3A1 full intracellular domain
(BFI) and purified the soluble proteins. First, we verified the con-
formations of the constructs by nuclear magnetic resonance
(NMR), and, according to the nicely dispersed 1H-15N-Heteronu-
clear Single QuantumCorrelation (HSQC) spectra, all the recom-948 Chemistry & Biology 21, 945–954, August 14, 2014 ª2014 Elsevibinant proteins are well folded and remain in a monomeric state.
Most of the amide resonance frequencies for PRY/SPRY domain
overlappedwith the peaks in the spectra for BFI (presented over-
laid in Figure S4). This suggests the structure of PRY/SPRY
domain in isolated form and in the context of the full-length
protein remains the same and that the 68-residue membrane
proximal region does not interact with the PRY/SPRY domain
intramolecularly. We performed ITC to measure the interactions
between these three BTN3A1 constructs and HMBPP (Fig-
ure 4A). While no binding was observed with the extracellular
BTN3A1 IgV domain, both the intracellular PRY/SPRY (B30.2)
domain and the BFI domain showed strong binding with dissoci-
ation constants (Kd) of 1.61 mM and 1.54 mM, respectively. The
interaction of HMBPP with BTN3A1 was enthalpy-driven with
an unfavorable entropy change. HMBPP binding to the full intra-
cellular domain (DH = 51.9 kJ/mol and TDS = 18.7 kJ/mol)
and the PRY/SPRY domain (DH = 49.4 kJ/mol and TDS =
16.4 kJ/mol) shares very similar enthalpy and entropy terms,
which reveals the binding site on BTN3A1 for phosphoantigens
is enclosed in the PRY/SPRY domain (Table S1). 1H-15N HSQC
titrations of HMBPP agreed with the ITC results. While there
were no chemical shift perturbations in the spectrum for the
IgV domain upon HMBPP titration (Figure S5), the effects from
HMBPP on the spectra of BFI and PRY/SPRY were very pro-
nounced. HMBPP-concentration-dependent chemical shift per-
turbations were observed in the spectra for both BFI (Figure 5A)er Ltd All rights reserved
Table 1. Activity of Compounds for Expansion of Vg9Vd2 T Cells
fromHumanPeripheral BloodMononuclearCells and Inhibition of
Cell Viability
Compound EC50 (mM)
Fold
difference
from HMBPP
Fold
difference
from 1aa
IC50
(mM)
Selectivity
index
HMBPP 0.00051 1.0 NA 0.50 980
IPP 36 71,000 NA ND ND
Risedronate 1.6 3,100 NA 61 38
1a 4.0 7,800 1 ND ND
1b 0.0054 10 740 0.60 110
1c 0.50 980 8 8.6 17
1d >10 >19,000 NA ND ND
NA, not applicable; ND, not determined.
aCompound 1a
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an HMBPP:protein ratio of 3:1. Combining ITC and NMR data,
we have demonstrated that HMBPP interacts with BTN3A1
at its intracellular domain at 1:1 ratio and is likely capable of
inducing significant conformational rearrangements in the intra-
cellular domain of BTN3A1.
To determine whether binding was specific to HMBPP or a
general property of phosphoantigens, we also tested whether
another potent phosphoantigen, (5-hydroxy-4-methylpent-3-
enyl)-phosphonooxyphosphinic acid (C-HDMAPP) could bind
to the internal domain (Figure S2). C-HDMAPP is a phospho-
nate analog of HBMPP (Boe¨dec et al., 2008). Interestingly,
C-HDMAPP exhibited similar energetics relative to HMBPP
when binding to the PRY/SPRY domain (Kd = 1.95 mM, DH =
47.1 kJ/mol, TDS = 14.5 kJ/mol). The data reveal that both
HMBPP and C-HDMAPP bind with high affinity to the intracel-
lular PRY/SPRY (B30.2) domain, but not the extracellular V
domain. C-HDMAPP has a slightly weaker interaction, which is
consistent with its activity in cellular assays (Boe¨dec et al.,
2008). Therefore, we have demonstrated that two different phos-
phoantigens bind strongly to the intracellular domain of BTN3A1.
Because IPP also acts as a direct phosphoantigen in cellular
assays, we tested its ability to interact with BTN3A1. However,
we were unable to measure directly the binding of IPP to
BTN3A1 by ITC. This is perhaps not surprising; given that the ac-
tivity in cellular assays is approximately 71,000-fold less for IPP
relative to HMBPP (Table 1), making the projected dissociation
constant well outside of the detection limit of ITC. Therefore,
we performed a competition ITC study to determine whether
increasing concentrations of IPP would affect the binding of
HMBPP to BTN3A1 (Figure S4). IPP dose-dependently
decreased the favorable enthalpy of HMBPP binding from a
DH of 51.9 kJ/mol to 47.7 kJ/mol and 38.7 kJ/mol at
IPP:BTN3A1 ratios of 10:1 and 100:1, respectively (Table S1).
IPP also dose-dependently made more favorable the TDS term
of HMBPP binding, changing it from 18.7 kJ/mol to 12.7 kJ/
mol and 6.78 kJ/mol at IPP:BTN3A1 ratios of 10:1 and 100:1
respectively. Taken together, the data show that IPP binds to
BTN3A1 with a much weaker affinity compared to HMBPP and
that both compounds compete for the same binding site within
the PRY/SPRY domain.Chemistry & Biology 21, 94Because compound 1b is expected to undergo metabolic
cleavage, resulting in accumulation of compound 1a, we exam-
ined the binding affinity between compound 1a and the BTN3A1
PRY/SPRY domain. Like IPP, the binding affinity of 1awas unde-
tectable in ITC when using compound 1a as the sole ligand, as
we had purposely chosen a weak phosphoantigen for the pro-
drug studies. However, as expected, compound 1a had a mark-
edly stronger effect on the HMBPP binding to the PRY/SPRY
domain relative to IPP (Figure 4B). Like IPP, compound 1a
dose-dependently decreased the favorable enthalpy of HMBPP
binding to BTN3A1. These effects also were measured at
1a:BTN3A1 ratios of 0:1(DH of 51.9 kJ/mol), 10:1 (49.1 kJ/
mol), and 100:1 (28.5 kJ/mol). Compound 1a also dose-depen-
dently made more favorable the TDS term of HMBPP binding at
IPP:BTN3A1 ratios of 10:1 (16.2 kJ/mol) and 100:1 (+5.19 kJ/
mol). These data fit well with the cellular data in that 1a is a
more potent phosphoantigen relative to IPP and would be
expected to have a stronger effect. Perhaps surprisingly, the
entropy term became positive at the highest concentration of
1a. This finding demonstrates that the prenyl alcohol and/or
the olefin position play a more important role in the phosphoan-
tigen-BTN3A1 interaction as compared to the distal phosphate
group. Thus, according to the ITC data, compound 1a may
induce conformational changes in the intracellular domain of
BTN3A1 similar to the ones induced by the stronger interaction
with HMBPP and absent in the interface with IPP.
To confirm that IPP and compound 1a do have direct inter-
actions with the intracellular domain of BTN3A1, 1H-15N HSQC
titrations of IPP and compound 1a into BFI were performed at
ligand:protein molar ratios of 0:1, 10:1, and 100:1. Both IPP
(Figure S6A) and compound 1a (Figure S6B) showed concentra-
tion-dependent perturbations in the spectra. These two sets of
titration data demonstrate that both IPP and compound 1a
bind to BFI at a similar binding site with only a limited number
of distinct differences in amide chemical shift perturbations be-
tween the two. In addition, the spectrum of compound 1a, but
not IPP, shows several chemical shift perturbations identical to
the ones observed in the titration of HMBPP (marked by arrows
on Figure S6C). Thus our NMR and ITC results are mutually
consistent and suggest that binding sites for IPP and compound
1a on the PRY/SPRY domain are quite similar, although each
compound is also involved in unique interactions with BTN3A1.
Prodrug 1b Stimulates Lysis of Daudi Lymphoma Cells
by Vg9Vd2 T Cells
To examine if compound 1b can induce T cell killing of malignant
cells, we examined the extent of Vg9Vd2 T cell lysis of Daudi lym-
phoma cells. Daudi cells were labeled with a fluorescent cell
membrane dye and mixed with purified Vg9Vd2 T cells at a ratio
of 5 to 1. Following coculture in the presence or absence of
0.1 mM test compounds, cells were stained with fluorescein iso-
thiocyanate (FITC)-Annexin V antibody and the cell profiles
examined by flow cytometry. The Vg9Vd2 T cells in combination
with compound 1b resulted in a significant increase in Annexin V
positive Daudi cells in comparison to no phosphoantigen
treatment (Figure 6A). Of the test compounds, only HMBPP
and compound 1b resulted in significant increase in Annexin V
positive Daudi cells (Figure 6B), with compound 1b promoting
greater T cell cytotoxic activity than HMBPP. In the absence of5–954, August 14, 2014 ª2014 Elsevier Ltd All rights reserved 949
Figure 4. Binding of HMBPP and Compound
1a to the Intracellular Domain of BTN3A1
(A) Isothermal titration calorimetry plots for the
interaction of HMBPP with the extracellular IgV
domain (gray line/dots), the full intracellular domain
(BFI) (black line/dots), or the isolated PRY/SPRY
(B30.2) domain (red line/dots).
(B) Isothermal titration calorimetry plots for the
interaction of the full intracellular domain (BFI) of
BTN3A1with HMBPP in the absence of compound
1a (red line/dots), or the presence of 10x com-
pound 1a (gray line/dots), or 100x compound 1a
(blue line/dots).
See also Figures S2 and S3 and Table S1.
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when the cells were treated with high concentrations of either
compound 1a or 1b (Figure 6C) for up to 72 hr at 10 mM. In
contrast, cell viability was significantly reduced when treated
with vorinostat.
DISCUSSION
In this study we have described the synthesis and evaluation of a
phosphoantigen prodrug. Surprisingly, this compound exhibits a
large increase in potency relative to the free phosphoantigen and
displays similar, if not greater, potency relative to HMBPP. Addi-
tionally, our analysis of the newly synthesized POM-modified
prodrug highlights several important conclusions (Figure 6D)
about the mechanisms that underlie phosphoantigen presenta-
tion: (1) phosphoantigen charge serves as a barrier to both
cellular entry and exit, (2) phosphoantigens bind to the intracel-
lular, and not extracellular, domain of BTN3A1, and (3) effective
delivery of phosphoantigens to the cytoplasm of malignant cells
induces their lysis by Vg9Vd2 T cells.
At the start of our studies, the molecular target of phosphoan-
tigenswas not known, sowe had deliberately chosen to combine
a moderate strength phosphoantigen with a well characterized
prodrug to ensure that we could measure any potency increases
generated by the prodrug strategy. To that end, it was quite sur-
prising to see that compound 1b rivals the potency of HMBPP,
the most potent known phosphoantigen. Additionally, relative
to the free phosphonic acid 1a, the pivaloyloxymethyl prodrug
1b is approximately 740 times more potent for expansion of
Vg9Vd2 T cells from peripheral blood following a three day stim-
ulation (Table 1). The increased activity is even more prevalent in
assays using shorter incubation times (Figure 3D), such as the
2 hr PBMC stimulation or the 4 hr Daudi lysis assay (Figure 6B).
In both of these assays, strong activity was seen with 0.1 mM
of compound 1b, while the activity of the free phosphonic
acid 1a at this concentration was not measureable. These950 Chemistry & Biology 21, 945–954, August 14, 2014 ª2014 Elsevier Ltd All rights reservedresults demonstrate that phosphoanti-
gen neutralization dramatically decreases
the time necessary for loading phos-
phoantigen presenting cells and suggest
that charged phosphoantigens enter cells
primarily by active uptake rather than
passive diffusion. There is clearly an op-
portunity for further increases in potency,which could be generated either through utilizing stronger phos-
phoantigens as templates or through utilizing different prodrug
motifs.
During the course of these studies, two groups reported bind-
ing of phosphoantigens to BTN3A1 via conflicting mechanisms
(Sandstrom et al., 2014; Vavassori et al., 2013). Initially, De Lib-
ero and colleagues (Vavassori et al., 2013) demonstrated extra-
cellular binding, whereas a recent paper by Adams (Sandstrom
et al., 2014) clearly showed intracellular binding. Our studies
are in strong agreement with those from the Adams Laboratory.
In addition to the calorimetry assay, we also see strong inter-
actions as assessed by NMR spectroscopy. Our results also
demonstrate the relative contribution of the prenyl alcohol group
and/or olefin position is more important than the second
phosphate group, because binding of HMBPP to BTN3A1 is
more strongly affected by 1a than IPP. Additionally, we have
compared the effects of different antigen binding on the full intra-
cellular domain and the PRY/SPRY domain by NMR. Our results
indicate that although the binding site for phosphoantigens is
localized in PRY/SPRY domain, the 68-residue membrane prox-
imal region, preceding PRY/SPRY, also undergoes major struc-
tural rearrangement upon binding (Figure 5C). In the future, it will
be interesting to determine the molecular details and the role of
the lipid bilayer in this process. While we are still in process of
resonance assignments, which can be time consuming for a pro-
tein of this size, our data are consistent with the recently pub-
lished crystal structure of the PRY/SPRY domain in complex
with HMBPP (Sandstrom et al., 2014). Our findings clearly pro-
mote a model in which intracellular binding of phosphoantigens
to BTN3A1 induces a conformational change, which either
propagates across the membrane to the extracellular region or
promotes an interaction with another intracellular protein, thus
allowing new transmembrane complex formation necessary for
recognition by the Vg9Vd2 T cell receptor.
Phosphoantigen prodrugs such as these may ultimately
become clinically useful. Currently, there has been only one
Figure 5. 1H-15N HSQC Titration of HMBPP into the Full-Length
Intracellular Domain and the PRY/SPRY Domain of BTN3A1
Compared to the PRY/SPRY domain, the full-length intracellular domain of
BTN3A1 (BFI) includes an additional membrane-proximal region of 68 residues
at the N terminus, which is demonstrated to be involved in the interaction with
HMBPP and to undergo significant structural changes upon binding.
(A) Chemical shift perturbations for the interaction of HMBPP and BFI at ratios
of 0:1 (black), 1:1 (blue), and 3:1 (red).
(B) Chemical shift perturbations for the interaction of HMBPP and the PRY/
SPRY domain at ratios of 0:1 (gray), 1:1 (orange), and 3:1 (green).
(C) Evidence for the involvement of the 68-residue membrane-proximal region
in interactionwith HMBPP: HSQC spectra of the free BFI (black), BFI + HMBPP
at 1:3 ratio (red), and PRY/SPRY + HMBPP at 1:3 ratio (green). Peaks that
belong to the 68-residue membrane-proximal region are absent in the spec-
trum of PRY/SPRY domain. Arrows indicate the peaks corresponding to the
amides from this region that have showed remarkable shifts upon binding to
HMBPP, thus suggesting significant structural rearrangements.
See also Figures S4–S6.
Figure 6. Bis-POM Prodrug 1b Promotes Lysis of Daudi Lymphoma
Cells by Vg9Vd2 T Cells
(A) DiD labeled Daudi cells were cocultured for 4 hr in the presence of Vg9Vd2
T cells at a 1:5 ratio and assessed by annexin V-FITC staining. Treatment with
compound 1b increases the number of annexin V positive Daudi cells.
(B) The mixture was incubated with various test compounds at 0.1 mM. Data
are represented as mean ± SD, n = 3, *p < 0.05 by ANOVA with Tukey’s post-
hoc analysis.
(C) 72 hr viability of Daudi cells incubated with compounds 1a and 1b relative
to vorinostat as a positive control. The mean of four replicates is presented,
*p < 0.05 by ANOVA with Tukey’s post-hoc analysis.
(D) A proposed prodrug model illustrates pathways for POM-modified
compound internalized and presented by antigen presenting cells. Charged
molecules such as phosph(on)ates have restricted membrane diffusion. By
neutralizing charge with a cell cleavable protecting group, one can encourage
diffusion into cells, and upon intracellular release ion trapping results in
elevated intracellular levels.
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trials, 4-bromo-3-hydroxy-3-methylbutyl diphosphate (BrHPP)
(Fournie´ et al., 2013). In these trials, the initial stimulation led to
an expansion of the Vg9Vd2 population, but this required large
intravenous doses and was limited in subsequent cycles of ther-Chemistry & Biology 21, 94apy. This dosing regimen was likely a consequence of limited
plasma stability of BrHPP (a diphosphate), because studies in
primates demonstrated rapid degradation in the plasma (Sicard
et al., 2005). Our results clearly show a time dependency to the
uptake of phosphoantigens by peripheral blood cells, with no
activation seen with HMBPP treatment of 2 hr (Figure 3D). This
explains the fact that a very high concentration of BrHPP was
needed to see any activation of Vg9Vd2 T cells in these
patients. We have shown that the phosphoantigen prodrug 1b
requires a much shorter incubation time. Therefore, this or other5–954, August 14, 2014 ª2014 Elsevier Ltd All rights reserved 951
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activation in human blood with significantly lower doses relative
to BrHPP.
Alternatively, others have used bisphosphonate drugs as
phosphoantigens in clinical trials (Van Beek et al., 2002); how-
ever, these compounds also have severely restricted phar-
macokinetics (e.g., rapid bone sequestration), low therapeutic
indexes, and the potential for side effects such as osteonecrosis.
Our data (Table 1) clearly show the advantage of using direct
phosphoantigens over an indirect phosphoantigen, as HMBPP
has a selectivity index that is 25 times greater than risedronate.
It is not clear whether other nitrogenous bisphosphonates,
such as zoledronate, have similarly narrow selectivity indexes.
However, we presume this to be the case as both the stimulation
and the cytotoxicity result from cellular inhibition of FPP syn-
thase, and at least one other group, has reported that shorter
durations of stimulation with zoledronate reduces its cytotoxic
effects (Nussbaumer et al., 2013). Compound 1b also has an
improved selectivity index relative to risedronate, and again we
believe it to be possible to make further gains in this area through
compound optimization.
Finally, it is important to note the functional consequences of
the phosphoantigen prodrug in the inducible lysis of cancer cells
(Figure 6). Compound 1b causes no discernable growth inhibi-
tion of Daudi cells at concentrations up to 10 mM and treatment
times up to 72 hr. However, when combined with Vg9Vd2 T cells,
compound 1b can induce the lysis of Daudi cells at 0.1 mM in
only 4 hr. Therefore, we believe that compounds such as 1b,
if effectively delivered to malignant cells, have the potential for
strong chemically induced cancer immunotherapy through re-
cruiting a targeted Vg9Vd2 T cell response.
In conclusion, these findings reveal several key mechanisms
of antigen recognition in the immune system and point to new
possibilities for development of clinical agents through under-
standing phosphoantigen structure activity relationships at the
molecular and cellular levels.
SIGNIFICANCE
We have described a phosphoantigen prodrug that func-
tions with exquisite potency. The prodrug defines key roles
of phosphoantigen charge, binding, and delivery. This strat-
egy has potential to impact clinical use of phosphoantigens,
which have been limited by poor pharmacokinetics, for
treatment or prevention of cancer and infectious disease.
EXPERIMENTAL PROCEDURES
Chemical Synthesis
Compound 4
To a stirred solution of n-BuLi (2.4 M in hexanes, 14.6 ml, 35.0 mmol) in tetra-
hydrofuran at 78C was added N,N-diisopropylamine (4.82 ml, 34.4 mmol).
The resulting solution was allowed to stir for 10 min and dimethyl methyl-
phosphonate (3.7 ml, 34.1 mmol) was added slowly via syringe. Once addition
was complete, the mixture was allowed to stir for 15 min during which time a
white precipitate formed. Prenyl bromide 3 (5.17 g, 34.7 mmol) was added
slowly via syringe, and after addition was complete the solution was allowed
to stir for an additional 30 min at –78C, allowed to warm to room temperature
unassisted, and stirred overnight. A saturated aqueous solution of NH4Cl was
added, the solution was extracted with Et2O, and the combined extracts were
dried (Na2SO4) and concentrated in vacuo. Final purification was achieved us-952 Chemistry & Biology 21, 945–954, August 14, 2014 ª2014 Elseviing flash column chromatography (3%MeOH in Et2O) to afford the target com-
pound in 65% yield (4.31 g) as a clear oil: 1H NMR d 5.07–5.00 (m, 1H), 3.67
(d, JHP = 11.1 Hz, 6H), 2.26–2.14 (m, 2H), 1.75–1.63 (m, 2H), 1.62 (s, 3H),
1.55 (s, 3H); 13C NMR d 132.9, 123.1 (d, JCP = 16.7 Hz), 52.2 (2C), 25.7, 25.0
(d, JCP = 137.9 Hz), 21.1 (d, JCP = 4.8 Hz), 17.7;
31P NMR d 34.2; high resolution
mass spectrometry (HRMS) (time-of-flight [TOF] MS electron impact [EI]) m/z
calculated for C8H18O3P (M+H)
+ 193.0994, found 193.0973.
Compound 1d
To a vigorously stirred solution of compound 4 (2.03 g, 10.6 mmol) in CH2Cl2
at room temperature were added SeO2 (0.602 g, 5.4 mmol), 4-hydroxy-
benzoic acid (0.150 g, 1.1 mmol), and t-BuOOH (70% in H2O, 5.48 ml,
42.6 mmol). The solution was allowed to stir for 19 hr and a saturated aqueous
solution of NaHCO3 was added. The solution was extracted (CH2Cl2), and the
combined extracts were dried (MgSO4) and concentrated in vacuo. The crude
material was dissolved in MeOH with stirring, cooled to 0C in an ice bath,
and NaBH4 (0.820 g, 21.6 mmol) was added in several aliquots. The solution
was allowed to stir for 2.5 hr, saturated aqueous NH4Cl was added, the solu-
tion was extracted (Et2O), and the combined extracts were dried (MgSO4) and
concentrated in vacuo. Final purification by flash column chromatography
(6%–10% MeOH in Et2O) afforded the target compound in 36% yield
(0.781 g) as a clear oil: 1H NMR d 5.37–5.31 (m, 1H), 3.89 (s, 2H), 3.66
(d, JHP = 11.7 Hz, 6H), 2.32–2.19 (m, 2H), 1.79–1.68 (m, 2H), 1.58 (s, 3H);
13C NMR d 136.3, 122.8 (d, JCP = 15.7 Hz), 67.5, 52.1 (d, JCP = 6.9 Hz, 2C),
24.3 (d, JCP = 138.6 Hz), 20.2 (d, JCP = 4.6 Hz), 13.3;
31P NMR d 34.3;
HRMS (TOF MS EI) m/z calculated for C8H17O4PNa (M+Na)
+ 231.0762, found
231.0745.
Compound 1a
Compound 1d (0.166 g, 0.80 mmol) was dissolved in CH2Cl2, and the mixture
was cooled to 0C in an ice bath. Collidine (0.425 ml, 3.2 mmol) and bromotri-
methylsilane (0.419 ml, 3.2 mmol) were added via syringe, and the reaction
was allowed to stir overnight. After the volatiles were removed, toluene was
added and removed in vacuo, and this cycle was repeated three times
providing a white solid. The solid was dissolved in aqueous NaOH (1.49 M,
2.15ml, 3.2 mmol), and the reaction mixture was stirred overnight. Themixture
was poured into an equal volume of acetone and cooled at 7C for a period of
24 hr to facilitate precipitation. Acetone and H2O were removed in vacuo,
the resulting solid was washed with acetone, dissolved in H2O, and washed
with diethyl ether. The aqueous phase was decolorized using activated
charcoal and concentrated in vacuo to provide the target salt in 77% yield
(137 mg): 1H NMR d 5.52–5.45 (m, 1H), 3.94 (broad singlet [br s], 2H), 2.23–
2.11 (m, 2H), 1.64 (br s, 3H), 1.45–1.33 (m, 2H); 13C NMR d 134.0, 128.6
(d, JCP = 17.3 Hz), 67.9, 29.5 (d, JCP = 126.9 Hz), 22.92, 13.5;
31P NMR
d 22.3; HRMS (TOF MS EI) m/z calculated for C6H12O4P (M-H)
- 179.0473,
found 179.0460.
Compounds 6 and 7
Phosphonate 4 (0.967 g, 5.0 mmol), sodium iodide (1.56 g, 10.4 mmol), and
pivaloyloxymethyl chloride (2.3 ml, 15.9 mmol) were added to acetonitrile un-
der an atmosphere of argon. The mixture was heated and held at reflux with
vigorous stirring overnight. Water and diethyl ether were added, and the
phases were separated. The aqueous phase was extracted with diethyl ether,
and the combined organic extracts were dried (Na2SO4) and concentrated in
vacuo. Final purification by flash column chromatography (30% Et2O in hex-
anes to 50% Et2O in hexanes) gave the target compound in 20% yield
(391 mg) as a clear oil: 1H NMR d 5.60 (d, JHP = 13.2 Hz, 4H), 5.04–4.97
(m, 1H), 2.26–2.14 (m, 2H), 1.84–1.71 (m, 2H), 1.61 (s, 3H), 1.53 (s, 3H), 1.16
(s, 18H); 13C NMR d 176.6 (2C), 133.0, 122.2 (d, JCP = 17.9 Hz), 81.1
(d, JCP = 6.5 Hz, 2C), 38.6 (2C), 26.6 (d, JCP = 136.8 Hz), 26.7 (6C), 25.4,
20.5 (d, JCP = 4.6 Hz), 17.5;
31P NMR d 32.7; HRMS (TOFMS EI)m/z calculated
for C18H33O7PNa (M+Na)
+ 415.1862, found 415.1868.
Compound 6 was accompanied by compound 7 and isolated in 30% yield
(0.46 g) as a clear oil: 1H NMR (300 MHz, CDCl3) d 5.67 (d, JHP = 13.4 Hz,
2H), 5.14–5.05 (m, 1H), 3.75 (d, JHP = 11.1 Hz, 3H), 2.36–2.20 (m, 2H), 1.91–
1.74 (m, 2H), 1.68 (s, 3H), 1.62 (s, 3H), 1.24 (s, 9H); 13C NMR (75 MHz,
CDCl3) d 176.6 (s), 134.7 (d, JCP = 1.8 Hz), 122.4 (d, JCP = 17.4 Hz), 81.4
(d, JCP = 5.9 Hz), 51.5 (d, JCP = 7.0 Hz), 38.4 (s), 26.6 (s, 3C), 25.3 (s), 25.0
(d, JCP = 35.1 Hz), 20.2 (d, JCP = 4.8 Hz), 17.3 (s);
31P NMR (121 MHz,
CDCl3) 33.7; HRMS (ESI
+) m/z calculated for C13H25O5PNa (M+Na)
+
315.1337, found: 315.1337.er Ltd All rights reserved
Chemistry & Biology
PA ProdrugCompound 1b
Compound 6 (0.361 g, 0.92 mmol) was dissolved in CH2Cl2 followed by addi-
tion of SeO2 (0.05 g, 0.45mmol), t-BuOOH (70%aqueous, 0.47ml, 3.65mmol),
and 4-hydroxybenzoic acid (0.013 g, 0.094 mmol). The mixture was stirred
vigorously overnight and then an aqueous solution of saturated NaHCO3
was added. The mixture was extracted with CH2Cl2, the combined organic ex-
tracts were dried (Na2SO4), and concentrated in vacuo. Final purification by
flash column chromatography (10% hexanes in Et2O) afforded the target prod-
uct in 45% yield (168 mg) as a clear oil: 1H NMR d 5.60 (d, JHP = 12.9 Hz, 4H),
5.34–5.28 (m, 1H), 3.91 (br s, 2H), 2.34–2.19 (m, 2H), 1.89–1.77 (m, 2H), 1.58
(s, 3H), 1.17 (s, 18H); 13C NMR d 176.9 (2C), 136.6, 122.7 (d, JCP = 15.7 Hz),
81.2 (d, JCP = 6.2 Hz, 2C), 67.9, 38.6 (2C), 26.4 (d, JCP = 138.2 Hz), 26.7
(6C), 20.2 (d, JCP = 5.2 Hz), 13.5;
31P NMR 32.6; HRMS (TOF MS EI)m/z calcu-
lated for C18H34O8P (M+H)
+ 409.1992, found 409.1995.
Compound 1c
Compound 7 (0.45 g, 1.54 mmol), SeO2 (0.09 g, 0.77 mmol), 4-hydroxyben-
zonic acid (0.02 g, 0.15 mmol), and t-BuOOH (0.79 ml, 6.15 mmol) were
dissolved in dichloromethane (10ml), and the reactionwas allowed to stir over-
night. The solution was quenched by addition of water and extracted with
diethyl ether. The organic portions were combined and washed with brine
and aqueous sodium thiosulfate, the solution was dried (MgSO4), filtered,
and concentrated in vacuo. The residue was purified via flash chromatography
(ether), and the desired product 1c was isolated as a yellow oil in 32% yield
(0.15 g, 43% based on recovered starting material): 1H NMR (300 MHz,
CDCl3) 5.71–5.61 (m, 2H), 5.44–5.34 (m, 1H), 3.98 (s, 2H), 3.75 (d, JHP =
11.3 Hz, 3H), 2.85 (br s, 1H), 2.38–2.28 (m, 2H), 1.92–1.81 (m, 2H), 1.66
(s, 3H), 1.24 (s, 9H); 13C NMR (75 MHz, CDCl3) d 177.0 (s), 136.4 (d, JCP =
1.4 Hz), 122.9 (d, JCP = 16.2 Hz), 81.5 (d, JCP = 6.3 Hz), 67.8 (s), 51.8
(d, JCP = 7.2 Hz), 38.6, 26.8 (s, 3C), 26.6 (d, JCP = 20.3 Hz), 20.3 (d, JCP =
4.8 Hz), 13.5 (s); 31P NMR (121 MHz, CDCl3) 33.5; HRMS (ESI
+)m/z calculated
for C13H25O6PNa (M+Na)
+ 331.1286, found: 331.1291.
Vg9Vd2 T Cell Isolation and Culture
Human peripheral blood mononuclear cell (PMBCs) were isolated from blood
from Research Blood Components using density centrifugation. Cells were
frozen in freezing media (10% DMSO, 90% fetal bovine serum [FBS]) in liquid
nitrogen until needed. 243 106 cells were resuspended in fresh T cell media
(RPMI-1640, 10% heat-inactivated FBS, 1x 4-(2-hydroxyethyl)-1-piperazinee-
thanesulfonic acid, pyruvate, nonessential amino acids, b-mercaptoethanol
[BME]) and added to 6-well plates. Cells were stimulated for 3 days unless
stated otherwise. Cells were cultured for another 11 days after compound
removal. Human IL-2 (5 ng/ml) was supplemented every 3 days. All experi-
ments were performed at least three times independently using at least two
different blood donors.
Flow Cytometry
Cells were washed and suspended in 100 ml of fluorescence-activated cell
sorting buffer (2% BSA in PBS). Total gamma delta T cell receptor (TCR)
was labeled using either FITC-anti-human Pan gamma delta TCR antibody
or anti-human Pan gamma delta TCR antibody followed by peridinin chloro-
phyll-eFluor 710-anti-mouse immunoglobulin G1. Cells were costained with
PE-conjugated anti-human CD3. Each step was done at 4 degrees for
30 min, washed twice, and then fixed in 3% paraformaldehyde before flow
analysis. Data were analyzed using FlowJo.
Cloning and Purification of Butyrophilin 3A1 Constructs
BTN3A1 constructs were purified based on the method of De Libero and col-
leagues (Vavassori et al., 2013) with some modifications (see Supplemental
Experimental Procedures).
Isothermal Titration Calorimetry
Calorimetric measurements of BTN3A1 domains were performed on a low vol-
ume Nano ITC. All experiments were carried out in a buffer of 50 mM Tris, pH
7.5, 100mMNaCl, 5 mMBME at 25Cwith a stirring speed of 200 rpm to mini-
mize the precipitation. Each titration consisted of twenty 2.5 ml injections with
300 s time intervals. The concentrations of protein samples were determined
by UV, and the compounds were prepared in the same buffer from the dilution
of 10 mM or 100 mM stock. The protein concentration ranged from 30 mM toChemistry & Biology 21, 9460 mM. The concentration of protein was examined after each ITC experi-
ment and a good solubility (>85%) was shown. Data analysis was done in
NanoAnalyze Software suite using an ‘‘independent’’ model. In all cases, a
stoichiometry of 1 ± 0.1 was revealed.
Nuclear Magnetic Resonance Spectroscopy
15N-labeled recombinant proteins were overexpressed in M9 medium supple-
mented with 15NH4Cl as the sole nitrogen source and purified as above. NMR
samples of 100–200 mM were prepared in a buffer of 50 mM Tris, pH 7.5,
100mMNaCl,5mMBME,7%D2O,1mM4,4-dimethyl-4-silapentane-1-sulfonic
acidas the internal standard. 1H-15NHSQCtitrationexperimentswereperformed
on Varian Inova 600 MHz spectrometer equipped with inverse-triple resonance
cyroprobe at 25C. All spectra were processed with NMRPipe (Delaglio et al.,
1995) and analyzed in CcpNmr Analysis (Vranken et al., 2005) software suite.
Daudi Killing Assay
TheDaudi killing assaywas performed basedon (Gomes et al., 2010)with slight
modification. Vg9Vd2 T cells were expanded from PMBCs by stimulation with
0.01 mMHMBPP for 3 days and expansion for 811 additional days as above.
At that time, Vg9Vd2 T cells were purified by negative selection using a kit.
Resulting populations were typically 98%99% Vg9Vd2 T cells as assessed
by flow cytometry. Daudi cells were stained with DiD (2 min in 4 mM DiD in
BSA/PBS), quenched by addition of an equal volumeof FBS, andwashed twice
in T cell media. Daudi cells (6 3 103) were mixed with 3 3 104 T cells and test
compounds to a final volume of 100 ml. Mixtures were incubated for 4 hr at
37 degrees then placed on ice for 5 min. Annexin V FITC (3 ml) was added
for 15 min on ice, then cells were diluted by addition of 200 ml binding buffer
(Becton Dickinson) and immediately analyzed by flow cytometry.
Proliferation Assay
Daudi proliferation was performed as described with the following parameters
(Wiemer et al., 2013). Cells/well (10,000) were added to 96-well plates in 100 ml
in the presence of test compounds. Cells were allowed to proliferate for 72 hr.
During the last 2 hr, cells were labeled with 5 ml of CellQuantiBlue reagent and
were scanned with a Victor plate reader.
Statistical Analysis
One-way ANOVA was used to calculate significance. Comparisons were done
relative to the control or between pairs of conditions. Columns in bar graphs
represent the mean ± SD. An a level of 0.05 was used.
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